You are here: Industry Insights > AstraZeneca

News List

AstraZeneca gets extension for Meronem withdrawal till Aug 31 expressbpd
August 02, 2017
Meronem is used for the treatment of serious infections in hospitalised patients
AZ immunotherapy gets FDA boost in early lung cancer pharmaphorum
August 01, 2017
The FDA may have offered struggling AstraZeneca a lifeline, granting a “breakthrough” designation for its cancer immunotherapy Imfinzi in early-stage lung cancer.
AstraZeneca and Merck establish strategic oncology collaboration worldpharmanews
July 28, 2017
AstraZeneca and Merck & Co., Inc., today announced that they have entered a global strategic oncology collaboration to co-develop and co-commercialise AstraZeneca's Lynparzafor multiple cancer types.
Blow for AstraZeneca as cancer combination fails pharmaphorum
July 27, 2017
After several years of growing expectation, AstraZeneca’s long-awaited MYSTIC immune-oncology trial has failed to show benefit over standard lung cancer therapy.
AstraZeneca to expand production at its Australian facility biospectrumasia
July 19, 2017
Three more production lines that will focus on innovative respiratory meds will be added to the North Ryde facility.
AstraZeneca to invest $100m to expand Sydney manufacturing plant pharmaceutical-technology
July 14, 2017
Pharmaceutical company AstraZeneca is investing an additional $100m to expand its manufacturing facility in North Ryde, Sydney, to develop inhaler products for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
NICE approves AstraZeneca’s COPD drug europeanpharmaceuticalreview
July 04, 2017
The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending roflumilast (Daxas, AstraZeneca) for chronic obstructive pulmonary disease (COPD).
AstraZeneca initiates recall of BRILINTA biospectrumasia
June 07, 2017
The voluntary nationwide recall of one lot of BRILINTA 90 mg professional sample bottles by AstraZeneca follows after a report of another medicine, ZURAMPIC in one bottle from that lot.
AstraZeneca signs deal to sell commercial rights for Seloken in Europe pharmaceutical-technology
May 27, 2017
AstraZeneca has entered an agreement to provide the commercial rights for Seloken/Seloken ZOK (metoprolol tartrate and metoprolol succinate respectively) and associated Logimax fixed-dose combination (metoprolol succinate and felodipine) treatments in Eur
AstraZeneca enters agreement with Recordati for Seloken in Europe europeanpharmaceuticalreview
May 25, 2017
AstraZeneca has entered into an agreement with Recordati for the commercial rights to Seloken/Seloken ZOK (metoprolol tartrate and metoprolol succinate respectively) and associated Logimax fixed-dose combination (metoprolol succinate and felodipine) treat

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page